Brief: Relay Therapeutics Announces Zovegalisib Granted Therapy Designation By FDA For Pik3ca-Mutant
03/02/2026 13:11
Feb 3 (Reuters) - Relay Therapeutics Inc RLAY.O: RELAY THERAPEUTICS ANNOUNCES ZOVEGALISIB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA FOR PIK3CA-MUTANT, HR+/HER2- ADVANCED BREAST CANCER Source text: ID:nGNX5Wy4tL Further company coverage: RLAY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relay Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Moderna, Kontoor Brands, Ralph Lauren
U.S. STOCKS ON THE MOVE- Intuit, Deere, Advance Auto Parts
U.S. STOCKS ON THE MOVE-Keysight Technologies, Relay Therapeutics, Ralph Lauren
Relay Therapeutics gains after $275 mln equity raise
Brief: Relay Therapeutics Announces Pricing Of Public Offering Of Common Stock